乌鸦传媒視頻

Adding pembrolizumab (Keytruda) to standard chemotherapy improved progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer, according to research presented at the Society of Gynecologic Oncology annual meeting.

In this 乌鸦传媒視頻 video, , an assistant professor of obstetrics, gynecology, and reproductive sciences at UC San Diego Health, discusses the study design and results, as well as what will come next.

Following is a transcript of his remarks:

NRG GY018, or Keynote-868, was a prospective, phase III, international, randomized, placebo-controlled and blinded clinical trial that looked to determine how the addition of pembrolizumab, an immune checkpoint inhibitor, to standard-of-care chemotherapy -- carboplatin and paclitaxel -- followed by maintenance pembrolizumab, of course, or placebo, would result in a benefit with respect to progression-free survival in patients with advanced stage or recurrent endometrial cancer.

The median progression-free survival in the pembrolizumab arm of the trial was not reached versus a median progression-free survival of 7.6 months with placebo. And that was reflective of a 70% reduction in the risk of disease progression or death. And the preliminary overall survival data for this trial are consistent with that finding. Of course, we have to wait for that data to mature.

In the mismatch repair-proficient [pMMR] population, which is a large chunk of endometrial cancer patients where we really haven't been able to identify effective therapeutic strategies, in NRG GY018, we again saw a 46% reduction in the risk of disease progression or death. So the median progression-free survival in the pembrolizumab arm of that population was 13.1 months versus 8.7 months with placebo. And that was a significant difference. And hopefully these findings will translate into our ability to incorporate immunotherapy for both the dMMR [mismatch repair deficiency] and the pMMR patients.

I was thrilled with the impact that we anticipate this will have in both the dMMR and the pMMR population. But in the same breath, it invigorates me and excites me to ask the next question. And so for all of us, our task is to say, "This is an incredible accomplishment, how can we capitalize on this? How can we design the next set of trials? How can we improve on these outcomes?"

And so my hope is that hopefully will catalyze and kind of drive that enthusiasm so that we can continue to improve the lives of women with these cancers.

Comment